GSK’s ViiV healthcare unit is countering rival HIV drugmaker Gilead’s recent global access moves with its own pledge to make at least 2 million doses of its long-acting pre-exposure prophylaxis (Pr | ...

DNA analysis company 23andme has been in trouble lately: data was breached in a 2023 hack, and this September the entire ...

After several high-profile failures, including BMS’ $1.5B breakup with Agenus, anti-TIGIT therapies are generating cautious ...

Mpox – formerly known as monkeypox – is rapidly spreading in several African countries, prompting the World Health ...

An activist invester has taken interest in pharma giant Pfizer, which despite becoming a household name during the pandemic ...

US hedge fund Starboard now holds 0.6% of Pfizer’s value as the drugmaker struggles with its post-pandemic financial ...

With a user base of more than 94 million—larger than the population of Germany—GCash is arguably the most popular Filipino ...

The idea is that if you move your focus to attracting people, you’ll ultimately attract the companies: If you build it (the ...

Chris Martin, Chairman and Non Executive Director of Myricx Bio said, “I am delighted to welcome Paolo to the board. He brings extensive leadership experience in R&D and commercialisation in the ...

Skyrizi had an estimated national TV ad spend of $93.7 million — the highest amount of any brand in the top 10 during this ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced the company's commitment to make at least two million doses of ...

After Kaléo unveiled a “redesign” of the in-office commercial team for its EpiPen rival Auvi-Q at the start of the month, the ...